The results of a study presented at the Annual European Congress of Rheumatology (EULAR 2019) finds the risk of bone mineral density (BMD) loss after denosumab discontinuation is associated with younger age, high bone turnover markers, and not receiving the bisphosphonate, zoledronate, prior to initiation of denosumab.

Press conference title (full): Can we avoid the loss of bone mineral density one year after denosumab discontinuation? The ReoLaus Bone Project.

Spokesperson: Dr Bérengère Aubry-Rozier. Center of Bone Diseases, and Lausanne University Hospital of Lausanne, Switzerland.

Abstract number: OP0085
[ Ссылка ]

Always consult your rheumatologist or healthcare provider for personalised medical advice or any questions regarding a medical condition and/or treatment.

свернуть